ESC Premium Access

A clinical view on BET inhibition in targeting residual risk in cardiovascular disease and diabetes.

Topic: Secondary Prevention
Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Resverlogix

Presentation

About the speaker

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
48 presentations
1 follower

4 more presentations in this session

Introduction - LDL-c: done deal, next epigenetics?

Speaker: Professor U. Laufs (Leipzig, DE)

Thumbnail

The real residual risk in patients with cardiovascular disease and diabetes: the promise of epigenetics.

Speaker: Professor E. Stroes (Amsterdam, NL)

Thumbnail

Understanding epigenetics - The potential rationale for BET inhibition in management of cardiovascular disease.

Speaker: Doctor J. Plutzky (Boston, US)

Thumbnail

Discussion and summary - LDL-c: done deal, next epigenetics? .

Speaker: Professor U. Laufs (Leipzig, DE)

Thumbnail

Access the full session

LDL-c: done deal, next epigenetics? (EBAC Accredited)

Speakers: Professor K. Ray, Professor U. Laufs, Professor E. Stroes, Doctor J. Plutzky, Professor U. Laufs
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk